James Lu is a Senior Principal Investigator at A*STAR Bioinformatics Institute (BII) in Singapore and leads the Drug Discovery Programme. Prior to his return to Asia in 2025, he served as a Distinguished AI Scientist at Genentech Inc. (USA), where he led pioneering efforts at the intersection of machine learning, pharmacology and clinical development. With over a decade of experience in computational modeling roles spanning Genentech, AstraZeneca, Roche and academia, Dr. Lu has advanced AI-driven approaches for PK/PD, systems pharmacology and disease progression modeling across multiple therapeutic areas.
Petra Schneider is a recognized pioneer in AI/ML-driven medicinal chemistry and drug discovery. With three decades of professional experience in both the biopharmaceutical industry and academia, she has also founded several successful startups. Her current research at ETH Zurich focuses on using AI for virtual compound screening and natural-product-inspired drug design.
Roland Huber is a Principal Investigator at A*STAR Bioinformatics Institute (BII) in Singapore and leads the AI and Emerging Technologies Programme. He works on RNA technology and applications and the development of RNA-based therapeutics. Areas of interest span RNA language models, structural and regulatory features in disease-associated RNAs in cancer and infectious disease as well as RNA manufacturing and formulation.